Skip to content

Replimune Group REPL Operating lease liabilities

Operating lease liabilities at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Immunome logo
ImmunomeIMNM
Roivant Sciences logo
Roivant SciencesROIV
Moderna logo
ModernaMRNA

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's operating lease liabilities?
Replimune Group (REPL) reported operating lease liabilities of -$207K in Q4 2025.
How has Replimune Group's operating lease liabilities changed year-over-year?
Replimune Group's operating lease liabilities decreased by 13.1% year-over-year, from -$183K to -$207K.
What is the long-term trend for Replimune Group's operating lease liabilities?
Over 2 years (2022 to 2025), Replimune Group's operating lease liabilities has grown at a 214.1% compound annual growth rate (CAGR), from -$73K to -$720K.